Biopharma & Life Sciences
Viatris Executive Compensation (FY25)
VTRS · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Scott Smith | Latest say-on-pay support = May 15, 2026 | Chief executive pay ratio ◇ To the median employee |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The paid brief on Viatris
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of October 17, 2026Latest filing (8-K): May 15, 2026
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Member, one year
274 figures on this page: 268 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
More on Viatris
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Scott Smith: $14,759,379 → $15,273,331 (3.5% higher)
Say-on-pay support: 95.6% → 96.9% (1.3 points higher)
CEO pay ratio: 304:1 → 327:1 (7.6% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Viatris' chief executive and what were they paid?
Scott Smith was paid $15,273,331 in total compensation as Chief Executive Officer for fiscal 2025. Compared with the $14,759,379 reported for fiscal 2024, Smith's total was 3.5% higher.
What was Viatris' say-on-pay result?
Shareholders supported the say-on-pay proposal with 96.9% of votes cast for or against in favor at the meeting held May 15, 2026 for fiscal 2025.
Which companies are in Viatris' peer group?
Companies named in the disclosed peer group include Abbott Laboratories, Amgen Inc., Bausch Health Companies Inc., Baxter International Inc. and Biogen Inc., among others.
What is Viatris' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 327:1, against median employee compensation of $46,729.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Rajiv Malik President | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Robert Coury Executive Chairman | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Michael Goettler Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Anthony Mauro President, Developed Markets | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Sanjeev Narula Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Scott Smith Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Brian Roman Former Chief Legal Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Scott Smith Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Doretta Mistras Chief Financial Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Corinne Le Goff Chief Commercial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Paul Campbell Chief Accounting Officer and Corporate Controller | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Sanjeev Narula Former Chief Financial Officer Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Brian Roman Chief Legal Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Scott Smith Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Corinne Le Goff Chief Commercial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Doretta Mistras Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Brian Roman Former Chief Legal Officer Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Andrew Enrietti Chief Administrative and Transformation Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Andrew Enrietti | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Andrew Enrietti | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Andrew Enrietti | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Brian Roman | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Brian Roman | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Corinne Le Goff | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Corinne Le Goff | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Doretta Mistras | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Doretta Mistras | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Scott A. Smith | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Scott A. Smith | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Scott Smith | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Doretta Mistras | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Andrew Enrietti | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Brian Roman | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Corinne Goff | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Melina Higgins Board chair | ◇ | ◇ | — | — | — | ◇ | ◇ |
Mark Parrish | ◇ | ◇ | — | — | — | — | ◇ |
Rajiv Malik | ◇ | ◇ | — | — | — | ◇ | ◇ |
JoEllen Lyons Dillon | ◇ | ◇ | — | — | — | — | ◇ |
Richard Mark | ◇ | ◇ | — | — | — | ◇ | ◇ |
James M. Kilts | ◇ | ◇ | — | — | — | ◇ | ◇ |
Leo Groothuis | ◇ | ◇ | — | — | — | — | ◇ |
Harry Korman | ◇ | ◇ | — | — | — | — | ◇ |
Elisha Finney | ◇ | ◇ | — | — | — | ◇ | ◇ |
W. Don Cornwell | ◇ | ◇ | — | — | — | ◇ | ◇ |
Rogério Vivaldi Coelho | ◇ | ◇ | — | — | — | — | ◇ |
Frank D'Amelio | ◇ | ◇ | — | — | — | — | ◇ |
Michael Severino | ◇ | ◇ | — | — | — | — | ◇ |
David Simmons | ◇ | ◇ | — | — | — | — | ◇ |
Scott A. Smith served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Board chair premium | ◇ |
| Compensation committee chair | ◇ |
Equity is delivered as restricted stock units.
Stock ownership guideline: 5x annual cash retainer ($750,000)
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Abbott Laboratories ABT
- Amgen Inc. AMGN
- Bausch Health Companies Inc. BHC
- Baxter International Inc. BAX
- Biogen Inc. BIIB
- Bristol-Myers Squibb Company BMY
- Gilead Sciences, Inc. GILD
- Novartis AG NVS
- Organon & Co. OGN
- Pfizer Inc. PFE
- Regeneron Pharmaceuticals, Inc. REGN
- Sandoz symbol not shown
- Sanofi S.A. SNY
- Teva Pharmaceutical Limited TEVA
- Zoetis Inc. ZTS
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 15, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | December 5, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | December 6, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | December 15, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | December 9, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | December 10, 2021 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Velarion Pro: every company page, peer tools and exports, one seat
One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Scott Smith (Chief Executive Officer), FY2025 total compensation $15,273,331 (base salary $1,448,654) [exec_comp, SEC accession 0001140361-26-013002, filed 2026-04-02]What this page does not include
Everything above is a fact Viatris disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Viatris sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
274 figures on this page: 268 cited to the filing that reported them, 6 calculated from figures it prints.
268 cited to the filing
6 calculated from the filing
Documents cited
- 0001140361-26-021672Proposal No. 2 – Approval, on a non-binding advisory basis, of the 2025 compensation of the named executive officers of the Company: For Against Abstain Broker Non-Votes
- 0001140361-26-0130022025 Summary Compensation Table · CEO Pay Ratio · Grants of Plan-Based Awards · Non-Employee Director Compensation for 2025 · and 2 more sections
- 0001140361-25-044544Proposal No. 2 – Approval, on a non-binding advisory basis, of the 2024 compensation of the named executive officers of the Company: For Against Abstain Broker Non-Votes
- 0001140361-25-0392632024 Summary Compensation Table
- 0001193125-24-272562
- 0001193125-24-2441732023 Summary Compensation Table
- 0001193125-23-296654
- 0001193125-23-2704372022 Summary Compensation Table
- 0001193125-22-301842
- 0001193125-21-359270
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Viatris executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/VTRS (accessed 2026).
Short form: data: Velarion
The paid brief for Viatris
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Viatris and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Viatris discloses
The companies named in VTRS's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}